Alto Neuroscience, Inc. — Investor Relations & Filings

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for neuropsychiatric conditions. The company's approach utilizes its Precision Psychiatry Platform, which leverages neurobiological data such as EEG and cognitive assessments to identify patient subpopulations most likely to respond to its targeted drug candidates. This biology-driven method aims to move beyond the traditional trial-and-error approach in mental health treatment by predicting clinical response. Alto's clinical-stage pipeline includes novel drug candidates designed to address core brain processes in conditions such as major depressive disorder, bipolar depression, and schizophrenia.